Skip to main content

Table 1 Baseline characteristic of participants according to group of intervention diets and TCF7L2 rs7903146 gene variant

From: The effect of TCF7L2 polymorphisms on inflammatory markers after 16 weeks of legume-based dietary approach to stop hypertension (DASH) diet versus a standard DASH diet: a randomised controlled trial

 

Total population

CC genotypes

TT + CT genotypes

 

DASH diet

Legume-based DASH diet

DASH diet

Legume-based DASH diet

DASH diet

Legume-based DASH diet

Participants, n

150

150

75

75

75

75

Age, years

55.5 (6.9)

55.4 (7.1)

55.1 (6.7)

55.2 (8.1)

55.6 (7.1)

55.5 (6.1)

Female, n (%)

85 (56.3)

86 (57.7)

42 (56.0)

45 (60.0)

43 (56.6)

41 (55.4)

hsCRP, mg/dl

3.6 (1.9–5.0)

3.7 (2.1–5.0)

3.6 (2.1–5.4)

3.7 (1.9–4.8)

3.5 (1.9–4.6)

3.8 (2.1–5.2)

MDA, µM

5.1 (3.7–7.7)

5.0 (3.6–8.3)

5.0 (3.7–7.6)

5.1 (3.4–8.3)

5.1 (3.4–8.3)

4.8 (3.6–7.9)

TNF-α, pg/ml

13.0 (11.2–15.9)

11.4 (9.8–15.8)

11.4 (9.8–13.4)

11.4 (9.8–13.4)

15.2 (12.6–17.9)

11.4 (9.9–16.5)

IL-6, pg/ml

4.3 (3.7–5.4)

3.8 (3.5–4.6)

3.9 (3.6–5.2)

3.7 (3.4–4.7)

4.5 (4.1–5.7)

3.9 (3.5–4.6)

Obese, n (%)

72 (48.0)

74 (49.3)

42 (56.0)

41 (54.7)

30 (40.0)

33 (44.0)

Physical activity levels, Met h/week

3.5 (2.7)

3.3 (2.7)

3.6 (2.8)

3.4 (2.3)

3.3 (2.6)

3.4 (3.0)

Academic degree, n (%)

18 (11.9)

22 (14.8)

6 (8.0)

6 (8.0)

12 (15.8)

16 (21.6)

Medication

      

Antihyperglycemic Medications

      

 Metformin, n (%)

55 (36.7)

69 (46.0)

32 (42.7)

39 (52.0)

23 (30.7)

30 (40.0)

 Sulfonylurea, n (%)

40 (26.5)

29 (19.3)

21 (28.0)

14 (18.7)

19 (25.3)

15 (20.0)

 Metformin + sulfonylurea, n (%)

45 (30.0)

31 (20.7)

20 (26.7)

13 (17.3)

25 (33.3)

18 (24.0)

 Metformin + thiazolidinedione, n (%)

5 (3.3)

11 (7.3)

2 (2.7)

9 (12.0)

3 (4.0)

2 (2.7)

 Others, n (%)

5 (3.3)

10 (6.7)

0 (0)

0 (0)

5 (6.7)

10 (13.3)

Lipid lowering drugs

      

 Statin use, n (%)

86 (57.0)

84 (56.4)

47 (62.7)

42 (56.0)

39 (51.3)

43 (57.3)

 Others, n (%)

1 (0.7)

4 (2.7)

0 (0.0)

2 (2.7)

1 (1.3)

2 (2.7)

Antihypertensive drugs

      

 ACE inhibitor/ARB use, n (%)

52 (34.7)

48 (32.0)

28 (37.3)

26 (34.7)

24 (32.0)

22 (29.3)

 Thiazide, n (%)

7 (4.7)

2 (1.3)

3 (4.0)

1 (1.3)

4 (5.3)

1 (1.3)

 Others, n (%)

10 (6.7)

8 (5.3)

8 (10.7)

4 (5.3)

2 (2.7)

4 (5.3)

 Asprin n (%)

28 (18.7)

28 (18.7)

11 (14.6)

13 (17.3)

17 (22.7)

15 (20.0)

Supplement

      

 Vitamin E

1 (0.7)

0 (0%)

0 (0%)

0 (0%)

1 (1.3%)

0 (0%)

 Vitamin D

32 (21.3)

34 (22.7)

17 (22.7)

18 (24.0)

15 (20.0)

16 (21.3)

 Vitamin B complex

17 (11.3)

15 (10.0)

7 (9.3)

9 (12.0)

10 (13.3)

6 (8.0)

 W-3 PUFA fatty acids

4 (2.7)

3 (2.0)

3 (4.0)

0 (0.0)

1 (1.3)

3 (4.0)

  1. Obese BMI ≥ 30 kg/m2
  2. Data are mean (SD) or median (interquartile range) unless otherwise indicated